Oncology Brand Tracker – Immune Checkpoint Inhibitors | 2020

Driven by DRG’s oncology expertise and real-world data capabilities, the Real World Brand Tracker is an interactive dashboard of regularly updated U.S. claims data that monitors and highlights the shifting market dynamics and the impact of events on immune checkpoint inhibitor prescribing.

QUESTIONS ANSWERED

How is the uptake for individual brands changing over time and across different U.S. regions and individual states?

Which brand is winning, and how does that vary by indication?

How does the dynamic regulatory environment for immune checkpoint inhibitor brands in the United States affect prescribing patterns of currently approved brands by indication?

What is the average claim charge for each brand? How does this compare to the reimbursed amount? How does each of these metrics vary by payer type?

In which types of facilities are patients receiving these brands?

KEY BENEFITS AND USES

Understand evolving market dynamics and correlate clinical and regulatory events to brand use by indication.

Track number of patients treated with immune checkpoint inhibitor brands over time.

Segment the data in multiple ways, including by state and treatment setting, to reveal pockets of opportunity.

Visualize trends in payer metrics including total claim amount, total claim paid, and top payers for immune checkpoint inhibitors.

Design appropriate clinical trial strategies based on rapidly evolving standards in treatment practices, as revealed by claims data.

Uncover pockets of opportunity for improved penetration and identify segments where brands are performing poorly.